Expleo Solutions Valuation
Is EXPLEOSOL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EXPLEOSOL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EXPLEOSOL (₹1326.65) is trading above our estimate of fair value (₹54.4)
Significantly Below Fair Value: EXPLEOSOL is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EXPLEOSOL?
Other financial metrics that can be useful for relative valuation.
What is EXPLEOSOL's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹20.59b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.1x |
Enterprise Value/EBITDA | 13.4x |
PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does EXPLEOSOL's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 27.5x | ||
KSOLVES Ksolves India | 42.3x | n/a | ₹14.4b |
532365 Dynacons Systems & Solutions | 30.7x | n/a | ₹16.0b |
534758 Cigniti Technologies | 10.9x | n/a | ₹36.1b |
ACCELYA Accelya Solutions India | 26.1x | n/a | ₹24.8b |
EXPLEOSOL Expleo Solutions | 19.8x | 27.3% | ₹20.6b |
Price-To-Earnings vs Peers: EXPLEOSOL is good value based on its Price-To-Earnings Ratio (19.8x) compared to the peer average (27.5x).
Price to Earnings Ratio vs Industry
How does EXPLEOSOL's PE Ratio compare vs other companies in the IN IT Industry?
Price-To-Earnings vs Industry: EXPLEOSOL is good value based on its Price-To-Earnings Ratio (19.8x) compared to the Indian IT industry average (37.9x).
Price to Earnings Ratio vs Fair Ratio
What is EXPLEOSOL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19.8x |
Fair PE Ratio | 30.2x |
Price-To-Earnings vs Fair Ratio: EXPLEOSOL is good value based on its Price-To-Earnings Ratio (19.8x) compared to the estimated Fair Price-To-Earnings Ratio (30.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.